Bing R F, Rosenthal F D
Acta Endocrinol (Copenh). 1982 Jun;100(2):221-3. doi: 10.1530/acta.0.1000221.
Twenty-eight patients with Graves' disease were treated with short-term antithyroid drug therapy. i.e. treatment was discontinued as soon as they became euthyroid. This was less than 4 months in all patients. Ten patients remained euthyroid, although in two of these, thyrotoxicosis recurred after the patients had been euthyroid for more than 2 months. The other 18 patients relapsed within 12 weeks of stopping therapy, and only two have become euthyroid after a further 12 month period of treatment. All patients who remitted were thyrotoxic for the first time whereas all patients with a past history of thyroid disease relapsed. Positive thyroid microsomal antibody titres were more frequent in patients who remitted, otherwise there were no indicators of a favourable outcome. The remission rate with antithyroid therapy which is only continued until the patient becomes euthyroid is similar to that for treatment lasting 12--18 months. Short-term therapy has the advantage of savings in both patient and clinician time.
28例格雷夫斯病患者接受了短期抗甲状腺药物治疗。也就是说，一旦患者甲状腺功能恢复正常，治疗即停止。所有患者的治疗时间均少于4个月。10例患者甲状腺功能维持正常，不过其中2例在甲状腺功能正常超过2个月后复发了甲状腺毒症。另外18例患者在停药12周内复发，只有2例在进一步治疗12个月后甲状腺功能恢复正常。所有缓解的患者均为首次发生甲状腺毒症，而所有有甲状腺疾病既往史的患者均复发。甲状腺微粒体抗体滴度阳性在缓解的患者中更为常见，除此之外，没有其他预后良好的指标。仅持续至患者甲状腺功能恢复正常的抗甲状腺治疗缓解率与持续12 - 18个月的治疗缓解率相似。短期治疗具有节省患者和医生时间的优势。
